Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

CD19 chimeric antigen receptor T (CAR T)-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this single center retrospective study of 85 patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Logue, Jennifer M., Zucchetti, Elisa, Bachmeier, Christina A., Krivenko, Gabriel S., Larson, Victoria, Ninh, Daniel, Grillo, Giovanni, Cao, Biwei, Kim, Jongphil, Chavez, Julio C., Baluch, Aliyah, Khimani, Farhad, Lazaryan, Aleksandr, Nishihori, Taiga, Liu, Hien D., Pinilla-Ibarz, Javier, Shah, Bijal D., Faramand, Rawan, Coghill, Anna E., Davila, Marco L., Dholaria, Bhagirathbhai R., Jain, Michael D., Locke, Frederick L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017820/
https://www.ncbi.nlm.nih.gov/pubmed/32327504
http://dx.doi.org/10.3324/haematol.2019.238634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017820/
https://www.ncbi.nlm.nih.gov/pubmed/32327504
http://dx.doi.org/10.3324/haematol.2019.238634

Ejemplares similares